SHANGHAI – A well-established French biotech company is working with one of China’s most authoritative state drug discovery organizations to develop a drug that could help the country tackle the growing incidence of breast cancer. Read More
Merus BV enticed Johnson & Johnson Development Corp. (JJDC) to join existing investors Novartis Venture Fund and Pfizer Venture Investments for a big pharma trifecta in a €31 million (US$42 million) extension to its Series B financing. Read More
Series A funding of $33 million will let Loxo Oncology Inc. move its lead compound through proof-of-concept research and push another into the clinic over the next three years or so, but the Delaware-incorporated firm still is not disclosing more about them. Read More
LONDON – A new understanding of how the neural circuits in the brain alter following exposure to addictive drugs such as cocaine could allow researchers to identify targets for drugs to treat addiction. Read More
• Amarin Corp. plc, of Dublin, said it was notified by the FDA that its scheduled advisory committee meeting Oct. 16 to discuss the proposed Vascepa (icosapent ethyl) ANCHOR indication will take place as planned, despite the federal government lapse in appropriations. Read More
• Forest Laboratories Inc., of New York, and Royalty Pharma Collection Trust jointly filed an additional lawsuit in the U.S. District Court for the District of Delaware against First Time US Generics LLC for infringement of patents related to Forest’s Savella (milnacipran HCL). Read More
• Abbvie Inc., of Chicago, shared results of a posthoc analysis of a Phase II study of Humira (adalimumab) for patients with hidradenitis suppurativa. The analysis showed that Humira produced a significant response rate in patients with moderate to severe disease at 16 weeks compared to placebo for the two dosing regimens assessed. Read More
• Atlab Pharma SAS, of Nantes, France, presented data at the European Cancer Congress in Amsterdam, from a Phase I trial with expansion cohorts involving 41 patients treated with fractionated doses of ATL101 for prostate cancer, reporting significant antitumor activity with a trend in dose-dependent effect on overall survival associated to a good tolerance and manageable myelotoxicity. Read More
